L’angiogenèse : une nouvelle cible thérapeutique des cancers thoraciques et ORL
| Autor: | Olivier Rixe, Laurent Taillade, Valentine Sultan-Amar, B. Billemont, Jean-Baptiste Meric, I. Alexandre |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Cancer Research
Chemotherapy business.industry Angiogenesis medicine.medical_treatment Head and neck cancer Cancer Hematology General Medicine medicine.disease Targeted therapy Radiation therapy Oncology Cancer research Medicine Radiology Nuclear Medicine and imaging Kinase activity business Nuclear medicine Lung cancer |
| Zdroj: | Bulletin du Cancer. 96:045-055 |
| ISSN: | 1769-6917 0007-4551 |
| DOI: | 10.1684/bdc.2008.0775 |
| Popis: | Angiogenesis or new blood vessel formation is a complex and fundamental event in the process of tumor growth and metastatic dissemination. Actually, most of antiangiogenic agents target the VEGF considered like the most potent proangiogenic factor. These molecules directly inhibit VEGF or the kinase activity of its receptor (VEGFR) and represent a significant therapeutic progress in several solid tumors types. First clinical studies of antiangiogenic agents in thoracic and laryngopharyngeal carcinomas have shown promise mainly in combination with other therapies (chemotherapy, other targeted therapies or radiotherapy). Besides common antiangiogenic therapies-induced adverse events, risks of bleeding caused by tumor necrosis mainly in squamous cell lung carcinomas have been observed during early clinical trials. Assessment of surrogate markers of target inhibition could allow a better selection of patients able to benefit from antiangiogenic treatments eventually combined with chemotherapy or molecules targeting others metabolic pathways. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|